Tag: Disarm Therapeutics October 26, 2022 New strategy shows potential to block nerve loss in neurodegenerative diseasesResearch into how key molecule triggers axon death may lead to new therapies.News Release October 20, 2020 Startup company founded by Washington University scientists acquired by Eli LillyDrugmaker purchases Disarm Therapeutics to develop treatments for neurodegenerative diseases.Medical Campus & Community Posts navigation